Article

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design Implications

2026-05-07

Abstract excerpt

<h4>Importance</h4> In multiple sclerosis (MS), high-efficacy disease-modifying therapies (HEDMTs) effectively control relapse-associated worsening (RAW), but progression independent of relapse activity (PIRA) remains inadequately addressed. As HEDMTs become the standard of care, developing new therapies that target this residual progression is a critical unmet need. <h4>Objective</h4> This study quantifies disa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bc7ab261-a2ee-57da-8168-01bf211f8cb7
DOI: 10.64898/2026.05.06.26352552

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design ImplicationsDOI 10.64898/2026.05.06.26352552Read

Effect of Early Treatment Intensity on Progression Independent of Relapse Activity and Disability Accumulation in Multiple SclerosisSemantic proximity Read

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.Semantic proximity Read

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records StudySemantic proximity Read

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activitySemantic proximity Read

Current status and future opportunities in modeling Multiple Sclerosis clinical characteristicsSemantic proximity Read

The association between disability progression, relapses, and treatment in early relapse onset MS: an observational, multi-center, longitudinal cohort studySemantic proximity Read

Biomarkers of Progression Independent of Relapse Activity—Can We Actually Measure It Yet?Semantic proximity Read

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factorsSemantic proximity Read

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisSemantic proximity Read

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudySemantic proximity Read

Oligoclonal Immunoglobulin Gamma Bands and Long-Term Disability Progression in Multiple Sclerosis: A Retrospective Cohort StudySemantic proximity Read

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.Semantic proximity Read